Evidence map›Paper›PMID 28719757›Full record

ArticleAmerican journal of respiratory and critical care medicine2018

The Plasma Concentration of MUC5B Is Associated with Clinical Outcomes in Paraquat-poisoned Patients.

Andrew A Monte, Hao Sun, Anna Malin Rapp-Olsson, Fahim Mohamed, Indika Gawarammana, Nicholas A Buckley, Christopher M Evans, Ivana V Yang, David A Schwartz

Erratum issuedOpen access · greenAbstract readLetter
In one paragraph

Article in American journal of respiratory and critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. The MUC5B Mucin Is Involved in Paraquat-Induced Lung Inflammation.Oxidative medicine and cellular longevity · 2020
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Andrew A Monte1 University of Colorado Aurora, Colorado.
Hao SunNanjing Medical University, Department of Emergency, Nanjing, China
Anna Malin Rapp-Olsson2 Rocky Mountain Poison & Drug Center Denver, Colorado.
Fahim Mohamed3 University of Peradeniya Peradeniya, Sri Lanka and.
Indika Gawarammana3 University of Peradeniya Peradeniya, Sri Lanka and.
Nicholas A Buckley3 University of Peradeniya Peradeniya, Sri Lanka and.
Christopher M Evans1 University of Colorado Aurora, Colorado.
Ivana V Yang1 University of Colorado Aurora, Colorado.
David A Schwartz1 University of Colorado Aurora, Colorado.
University of Colorado System · USUniversity of Peradeniya · LKWashington Poison Center · US

Funding

Mechanisms of Familial Pulmonary FibrosisP01HL092870 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLACKWELL, TIMOTHY S. · 2010 to 2020
$21.6M
Colorado Clinical and Translational Science Institute (UL1)UL1TR000154 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$20.4M
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)R01HL097163 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI FINGERLIN, TASHA E., SCHWARTZ, DAVID ALBERT · 2009 to 2018
$16.4M
Role of Mucin in Lung Homeostasis and PathophysiologyR01HL080396 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Christopher M Evans · 2009 to 2026
$8.6M
Mechanisms of lung macrophage programming by MUC5B during health and diseaseR01HL130938 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI EVANS, CHRISTOPHER M · 2016 to 2025
$5.2M
MUC5B, a novel therapeutic target for Idiopathic Pulmonary Fibrosis (IPF)UH3HL123442 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2016 to 2018
$4.8M
MUC5B, a novel therapeutic target for Idiopathic Pulmonary Fibrosis (IPF)UH2HL123442 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2014 to 2015
$3.0M
PERSONALIZING EMERGENCY/ACUTE THERAPEUTICS UTILIZING SYSTEMS BIOLOGY (PEGASUS)R35GM124939 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI MONTE, ANDREW ALBERT · 2017 to 2021
$2.1M
Functional Genetics in Idiopathic Pulmonary FibrosisR33HL120770 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2016 to 2018
$1.6M
An Integrated Approach to Personalized MedicineK23GM110516 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI MONTE, ANDREW ALBERT · 2014 to 2016
$588k
Functional Genetics in Idiopathic Pulmonary FibrosisR21HL120770 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2014 to 2015
$424k
Genetic and Epigenetic Changes in MUC5B and Fibrosing Interstitial Lung DiseaseI01BX001534 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI SCHWARTZ, DAVID ALBERT · 2013 to 2016
–
BLRD VA I01 BX001534NCATS NIH HHS UL1 TR000154NHLBI NIH HHS P01 HL092870NHLBI NIH HHS R01 HL080396NHLBI NIH HHS R01 HL097163NHLBI NIH HHS R01 HL130938NHLBI NIH HHS R21 HL120770NHLBI NIH HHS R33 HL120770NHLBI NIH HHS UH2 HL123442NHLBI NIH HHS UH3 HL123442NIGMS NIH HHS K23 GM110516NIGMS NIH HHS R35 GM124939
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Patient Outcome AssessmentAdultFemaleHerbicidesHumansMaleMiddle AgedMucin-5BParaquatSri LankaYoung AdultHerbicidesMUC5B protein, humanMucin-5BParaquat

Identifiers

PMID28719757
PMCPMC6005237
OpenAlexW2738088104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.